Resource

FDA Response to CSPI Letter

Re: Products Sold as Opioid WIthdrawal Aids

ShareThis

FDA responds to CSPI's December 8, 2017 letterĀ to Scott Gottlieb, FDA Commissioner, and Steven Tave, Director of the FDA Office of Dietary Supplement Program urging the agency to take enforcement action to protect consumers from dietary supplements that are marketed as opioid withdrawal aids.